Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
Thyroid Cancer
DRUG: Anlotinib|PROCEDURE: surgery|PROCEDURE: core needle biopsy
Objective response rate, ORR, at the time point of 18 weeks
R0/1 resection rate, R0/1 resection rate if operable, at the time of surgery|Disease control rate, DCR, at the time point of 18 weeks|Overall survival, OS, up to 3 years|Adverse Events, AEs, from the first drug administration to within 90 days after surgery
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.